We would like to thank members of our advisory group who provided expert advice and comments on the protocol and a draft of this report: Professor Graham Jackson, Honorary Clinical Professor of Clinical Haematology Northern Institute for Cancer Research, Newcastle University (Professor Jackson was a Chief Investigator on the MMIX Trial); Dr Alastair Smith, Consultant Haematologist, Southampton General Hospital (Dr Smith has received honoraria from Ortho-Biotech and Celgene during the past 2 years for invited lectures, was a local investigator in the MMIX Trial, undertakes unpaid patient and carer education, and reviews research grant applications for Myeloma UK); Mrs Joan Smith, Secretary, North Manchester & Bury Myeloma Support Group; and Paul Tappenden, Senior Research Fellow, Health Economics and Decision Science, School of Health and Related Research (ScHARR), University of Sheffield.

We would also like to thank the MMIX Trial team for providing unpublished data for this report, in particular: Professor Anthony Child, Professor Gareth Morgan, Dr Sue Bell, Dr Walter Gregory, Mrs Kim Cocks and Mr Alex Szubert.

We are also grateful to Susan Baliss, Finance Manager – Costing, Southampton University Hospitals NHS Trust; Karen Welch, Information Scientist, SHTAC, University of Southampton, for generating and running the literature searches; and Jonathan Shepherd, Principal Research Fellow, SHTAC, for reviewing a draft of this report.